Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Stefan Sillau to Parkinson Disease

This is a "connection" page, showing publications Stefan Sillau has written about Parkinson Disease.

 
Connection Strength
  
 
 
2.188
  
  1. Yilmaz S, Aslam S, Sillau S, Katz M, Kluger B. Bridging the gap: Evaluating a community-based palliative care intervention for underserved patients with Parkinson's disease. Parkinsonism Relat Disord. 2026 May; 146:108262.
    View in: PubMed
    Score: 0.149
  2. Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, Thompson JA, Seawalt T, Klawitter J, Sempio C, Chin G, Forman L, Fullard M, Hawkins T, Seeberger L, Newman H, Vu D, Leehey MA. Short-Term Cannabidiol with ?-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Mov Disord. 2024 May; 39(5):863-875.
    View in: PubMed
    Score: 0.130
  3. Bock MA, Macchi ZA, Harrison KL, Katz M, Dini M, Jones J, Ayele R, Kutner JS, Pantilat SZ, Martin C, Sillau S, Kluger B. Does a novel community-based outpatient palliative care intervention for Parkinson's disease and related disorders improve care? Qualitative results from patients and care partners. Palliat Med. 2024 Feb; 38(2):240-250.
    View in: PubMed
    Score: 0.129
  4. Kluger BM, Katz M, Galifianakis NB, Pantilat SZ, Hauser JM, Khan R, Friedman C, Vaughan CL, Goto Y, Long SJ, Martin CS, Dini M, McQueen RB, Palmer L, Fairclough D, Seeberger LC, Sillau SH, Kutner JS. Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease. JAMA Neurol. 2024 01 01; 81(1):39-49.
    View in: PubMed
    Score: 0.128
  5. Domen CH, Sillau S, Liu Y, Leehey MA. Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds. Mov Disord. 2024 Jan; 39(1):222-223.
    View in: PubMed
    Score: 0.128
  6. Mahes A, Macchi ZA, Martin CS, Katz M, Galifianakis NB, Pantilat SZ, Kutner JS, Sillau S, Kluger BM. The "Surprise Question" for Prognostication in People With Parkinson's Disease and Related Disorders. J Pain Symptom Manage. 2024 01; 67(1):e1-e7.
    View in: PubMed
    Score: 0.126
  7. Domen CH, Sillau S, Liu Y, Adkins M, Rajkovic S, Bainbridge J, Sempio C, Klawitter J, Leehey MA. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and ?9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Mov Disord. 2023 07; 38(7):1341-1346.
    View in: PubMed
    Score: 0.123
  8. Bock M, Katz M, Sillau S, Adjepong K, Yaffe K, Ayele R, Macchi ZA, Pantilat S, Miyasaki JM, Kluger B. What's in the Sauce? The Specific Benefits of Palliative Care for Parkinson's Disease. J Pain Symptom Manage. 2022 06; 63(6):1031-1040.
    View in: PubMed
    Score: 0.112
  9. Koljack CE, Miyasaki J, Prizer LP, Katz M, Galifianakis N, Sillau SH, Kluger BM. Predictors of Spiritual Well-Being in Family Caregivers for Individuals with Parkinson's Disease. J Palliat Med. 2022 04; 25(4):606-613.
    View in: PubMed
    Score: 0.111
  10. Buard I, Lattanzio L, Stewart R, Thompson S, Sjoberg K, Hookstadt K, Morrow M, Holden SK, Sillau S, Thaut M, Kluger B. Randomized controlled trial of neurologic music therapy in Parkinson's disease: research rehabilitation protocols for mechanistic and clinical investigations. Trials. 2021 Aug 28; 22(1):577.
    View in: PubMed
    Score: 0.109
  11. Rietcheck HR, Maghfour J, Rundle CW, Husayn SS, Presley CL, Sillau SH, Liu Y, Leehey MA, Dunnick CA, Dellavalle RP. A Review of the Current Evidence Connecting Seborrheic Dermatitis and Parkinson's Disease and the Potential Role of Oral Cannabinoids. Dermatology. 2021; 237(6):872-877.
    View in: PubMed
    Score: 0.104
  12. Trang I, Katz M, Galifianakis N, Fairclough D, Sillau SH, Miyasaki J, Kluger BM. Predictors of general and health-related quality of life in Parkinson's disease and related disorders including caregiver perspectives. Parkinsonism Relat Disord. 2020 08; 77:5-10.
    View in: PubMed
    Score: 0.100
  13. Miyasaki JM, Kluger BM, Sillau S, Katz M, Galifianakis N, Prizer LP. Associations between spiritual well-being and quality of life in Parkinson disease. Ann Palliat Med. 2020 05; 9(3):1288-1289.
    View in: PubMed
    Score: 0.099
  14. Macchi ZA, Koljack CE, Miyasaki JM, Katz M, Galifianakis N, Prizer LP, Sillau SH, Kluger BM. Patient and caregiver characteristics associated with caregiver burden in Parkinson's disease: a palliative care approach. Ann Palliat Med. 2020 Feb; 9(Suppl 1):S24-S33.
    View in: PubMed
    Score: 0.096
  15. Prizer LP, Kluger BM, Sillau S, Katz M, Galifianakis N, Miyasaki JM. Correlates of spiritual wellbeing in persons living with Parkinson disease. Ann Palliat Med. 2020 Feb; 9(Suppl 1):S16-S23.
    View in: PubMed
    Score: 0.096
  16. Holden SK, Koljack CE, Prizer LP, Sillau SH, Miyasaki JM, Kluger BM. Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison. Parkinsonism Relat Disord. 2019 08; 65:172-177.
    View in: PubMed
    Score: 0.094
  17. Holden SK, Medina LD, Hoyt B, Sillau SH, Berman BD, Goldman JG, Weintraub D, Kluger BM. Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. Mov Disord. 2018 11; 33(11):1760-1768.
    View in: PubMed
    Score: 0.089
  18. Sebring K, Shattuck J, Berk J, Boersma I, Sillau S, Kluger BM. Assessing the validity of proxy caregiver reporting for potential palliative care outcome measures in Parkinson's disease. Palliat Med. 2018 10; 32(9):1522-1528.
    View in: PubMed
    Score: 0.088
  19. Buard I, Sciacca DM, Martin CS, Rogers S, Sillau SH, Greher MR, Chen R, Kluger BM. Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease. Mov Disord. 2018 03; 33(3):489-491.
    View in: PubMed
    Score: 0.084
  20. Prizer LP, Kluger BM, Sillau S, Katz M, Galifianakis NB, Miyasaki JM. The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms. Parkinsonism Relat Disord. 2020 09; 78:61-65.
    View in: PubMed
    Score: 0.025
  21. Kluger BM, Miyasaki J, Katz M, Galifianakis N, Hall K, Pantilat S, Khan R, Friedman C, Cernik W, Goto Y, Long J, Fairclough D, Sillau S, Kutner JS. Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders: A Randomized Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):551-560.
    View in: PubMed
    Score: 0.025
  22. Kluger BM, Katz M, Galifianakis N, Pantilat SZ, Kutner JS, Sillau S, Gritz M, Jones J, Fairclough D, Sumrall M, Hall K, Miyasaki J. Does outpatient palliative care improve patient-centered outcomes in Parkinson's disease: Rationale, design, and implementation of a pragmatic comparative effectiveness trial. Contemp Clin Trials. 2019 04; 79:28-36.
    View in: PubMed
    Score: 0.023
  23. Klepitskaya O, Liu Y, Sharma S, Sillau SH, Tsai J, Walters AS. Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. Neurology. 2018 09 11; 91(11):e1013-e1021.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)